SCHEMBL11976537

SCHEMBL11976537

O=C(O)Cc1ccc2ccn(Cc3cccc(Oc4ccccc4)c3)c2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.51
HDAC8 Q9BY41 2/20 0.49
MCL1 Q07820 1/20 0.47
RHEB Q15382 1/20 0.45
SRD5A2 P31213 3/20 0.44
NR3C1 P04150 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCR8 P51685 1/20 0.43
FAAH O00519 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
BACE1 P56817 1/20 0.43
ICMT O60725 1/20 0.42
HTR6 P50406 1/20 0.42
P2RX3 P56373 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11977068 0.88 HDAC8 (0.60) HDAC8LMNAHDAC3HDAC4HDAC1
SCHEMBL8387304 0.86 HDAC8 (0.55) HDAC8KDM4EALDH1A1BACE1HTR6
SCHEMBL11977343 0.85 HDAC8 (0.52) HDAC8KDM4EALDH1A1BACE1HTR6
SCHEMBL11976532 0.84 HTR6 (0.53) HDAC8LMNAGAABACE1HTR6
SCHEMBL11977062 0.82 HDAC8 (0.49) HDAC8KDM4EALDH1A1BACE1
SCHEMBL11976525 0.82 LMNA (0.54) HDAC8KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL11975783 0.82 EPHX2 (0.47) HDAC8KDM4EALDH1A1BACE1HTR6
SCHEMBL11976844 0.80 HTR6 (0.56) HDAC8KDM4EALDH1A1LMNAGAA
SCHEMBL415441 0.79 FFAR1 (0.68) FFAR1SRD5A2NR3C1FAAHFFAR4
SCHEMBL11976841 0.79 MAPT (0.48) HDAC8KDM4EALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359350-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-06-07 US disclosed
US-9359350-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-06-07 US disclosed
US-20150203490-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-23 US disclosed
US-20150203490-A1 RING-FUSED COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2015-07-23 US disclosed
US-8987473-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
US-8987473-B2 Ring-fused compound SATO PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
WO-2012102405-A1 RING-FUSED COMPOUND 佐藤製薬株式会社 (JP) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203490-A1 RING-FUSED COMPOUND URB2, RCOR1, RCC2 FFAR1 1968/4885HDAC8 2042/4885MCL1 2189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.